logo

The Next-Generation of Small, Cost-Effective and Mobile Brain Scanner for an Early Detection of Alzheimer’s Disease

Sector: Manufacturing (Industrial) • Location: Switzerland

Source: EU Funding & Tenders Portal

Project
Ended

Alzheimer’s (AD) is a global epidemic with 50 M people suffering it and 76 M expected by 2030 (related costs near $1 Tri in 2018). To diminish its burden, an early detection is crucial, specially when modifying treatments become available. The most accurate method to measure AD hallmarks is positron emission tomography (PET), but current PET scanners are multi-modal, whole-body, room-filling, expe

Project Information FAQ

Project Information

3 Q
The project “The Next-Generation of Small, Cost-Effective and Mobile Brain Scanner for an Early Detection of Alzheimer’s Disease” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Switzerland. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Alzheimer’s (AD) is a global epidemic with 50 M people suffering it and 76 M expected by 2030 (related costs near $1 Tri in 2018). To diminish its burden, an early detection is crucial, specially when modifying treatments become available. The most accurate method to measure AD hallmarks is positron emission tomography (PET), but current PET scanners are multi-modal, whole-body, room-filling, expensive to acquire (€1-5 M) and not commonly used. Thus, there is still a need for more efficient diagnostic tools to detect AD at an early stage to adopt the best live-lasting treatment. Positrigo is a Swiss start-up, founded with the goal of provide an efficient PET tool for the early diagnosis of neurodegenerative diseases. Our technology has enabled us to develop a first prototype of BPET which has been preliminary tested in the laboratory with high performance. BPET is a dedicated mobile brain scanner with the size of a drying hood, 10x less capital (€400 k instead of millions) and 5x less operational expenses than current scanners. It will greatly improve early diagnosis of AD, facilitate its treatment follow-up and contribute to accelerate drug development programs, with a 10x increase in scanning capacity. BPET can be sold to hospitals and clinical research organizations, tailored to the needs of patients and doctors, and it can enable new case uses of brain PET (e.g many scanners used in parallel, wider populations, in larger cohort research studies). Diverse hospitals have shown their interest in BPET and their support for its complete development for its potential applications and impact. To launch BPET in the healthcare market we need its CE marking, clinical validation and industrial adaptation, so a total of €2.5M for phase 2 will be requested. BPET project will pave the way for our company to be established as an innovative alternative in scanner-based diagnosis, boosting our company to grow and reach around €30 M profits and a ROI of 7.4 after 5 years.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data